Novo Nordisk Oral Wegovy Real-World Data: Weight Loss Continues After Switching from Injectable
nashnova research
Novo Nordisk released the first real-world evidence showing 194 patients who switched from weight-loss injections to the Wegovy oral pill lost an additional ~4% of body weight within three months — suggesting the pill can not only hold the injection's results but push them further.
Can the pill actually hold the ground the injection gained?
194 patients with obesity or overweight switched from injections to the Wegovy oral pill and lost an additional ~4% of body weight — about 8.8 lbs (≈4 kg) — over three months.
This means → the oral pill is not a step-down option; it kept reducing weight on top of what the injection had already achieved.
This is the first real-world data on the injection-to-pill switch. Until now, the market had only clinical-trial results — no evidence from routine care settings.
Who lost the most weight?
About two in five patients achieved a weight loss of 5% or more — a striking proportion for just a three-month window.
The share of patients with a BMI at or above 30 — the medical threshold for obesity — fell by more than 21%.
In plain terms = the numbers moved beyond the scale: a meaningful group of patients crossed out of the clinical "obese" category entirely.
Why are patients willing to trade the needle for a pill?
Chief Scientific Officer Martin Holst Lange said: "Subcutaneous Wegovy can now be interchanged with the Wegovy tablet — patients can expect the same tolerability and safety, and actually lose a little more weight."
Roughly 75% of patients said they were satisfied with the switch; nearly 70% reported better-fitting clothes, and about 51% said their eating habits improved.
This reflects a clear shift in patient preference — especially among frequent travelers who find it impractical to refrigerate an injectable. The pill solves a real lifestyle pain point.
What are the limits of this data?
The data come from routine telehealth visits on the Ro platform; timing and completeness vary, and some data were self-reported, introducing potential bias.
Novo Nordisk itself acknowledged the results "cannot be generalized to the broader population"; real-world studies measure association, not causation.
This means → the data are a positive signal, not a verdict. Whether the pill can replicate the injection's results in a larger, more diverse population remains the market's key validation milestone.
市场有风险，内容仅供研究参考，不构成投资建议。